La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !
NATCO Pharma Gestion
Gestion contrôle des critères 4/4
Le PDG NATCO Pharma's est Rajeev Nannapaneni, nommé en Jun2012, a un mandat de 12.17 ans. détient directement 0.63% des actions de la société, d'une valeur de ₹ 1.64B. La durée moyenne de mandat de l'équipe de direction et du conseil d'administration est respectivement 7.5 ans et 9.6 ans.
Informations clés
Rajeev Nannapaneni
Directeur général
₹20.9m
Rémunération totale
| Pourcentage du salaire du PDG | n/a |
| Durée du mandat du directeur général | 12.2yrs |
| Propriété du PDG | 0.6% |
| Durée moyenne d'occupation des postes de direction | 7.5yrs |
| Durée moyenne du mandat des membres du conseil d'administration | 9.6yrs |
Mises à jour récentes de la gestion
Recent updates
NATCO Pharma Limited's (NSE:NATCOPHARM) Shares Bounce 26% But Its Business Still Trails The Market
Aug 13
If EPS Growth Is Important To You, NATCO Pharma (NSE:NATCOPHARM) Presents An Opportunity
Jul 15NATCO Pharma (NSE:NATCOPHARM) Seems To Use Debt Rather Sparingly
Jun 30NATCO Pharma Limited's (NSE:NATCOPHARM) Earnings Are Not Doing Enough For Some Investors
Jun 14NATCO Pharma Limited (NSE:NATCOPHARM) Exceeded Expectations And The Analyst Consensus Has Been Reviewing Its Models
May 30Calculating The Fair Value Of NATCO Pharma Limited (NSE:NATCOPHARM)
May 09Does NATCO Pharma (NSE:NATCOPHARM) Deserve A Spot On Your Watchlist?
Apr 03NATCO Pharma (NSE:NATCOPHARM) Is Due To Pay A Dividend Of ₹1.25
Feb 21NATCO Pharma Limited Just Beat EPS By 223%: Here's What Analysts Think Will Happen Next
Feb 18NATCO Pharma Limited (NSE:NATCOPHARM) Surges 25% Yet Its Low P/E Is No Reason For Excitement
Feb 17Is NATCO Pharma (NSE:NATCOPHARM) A Risky Investment?
Jan 25An Intrinsic Calculation For NATCO Pharma Limited (NSE:NATCOPHARM) Suggests It's 37% Undervalued
Jan 09Does NATCO Pharma (NSE:NATCOPHARM) Deserve A Spot On Your Watchlist?
Dec 13An Intrinsic Calculation For NATCO Pharma Limited (NSE:NATCOPHARM) Suggests It's 42% Undervalued
Sep 30Here's Why We Think NATCO Pharma (NSE:NATCOPHARM) Might Deserve Your Attention Today
Sep 12NATCO Pharma (NSE:NATCOPHARM) Is Paying Out A Larger Dividend Than Last Year
Aug 12Is NATCO Pharma (NSE:NATCOPHARM) A Risky Investment?
Jul 16NATCO Pharma Limited (NSE:NATCOPHARM) Shares Could Be 44% Below Their Intrinsic Value Estimate
Apr 20Is NATCO Pharma Limited (NSE:NATCOPHARM) Trading At A 46% Discount?
Dec 20NATCO Pharma's (NSE:NATCOPHARM) Upcoming Dividend Will Be Larger Than Last Year's
Aug 12Does NATCO Pharma (NSE:NATCOPHARM) Have A Healthy Balance Sheet?
Jun 23Broker Revenue Forecasts For NATCO Pharma Limited (NSE:NATCOPHARM) Are Surging Higher
Jun 02NATCO Pharma's (NSE:NATCOPHARM) Shareholders Will Receive A Bigger Dividend Than Last Year
Feb 22Estimating The Intrinsic Value Of NATCO Pharma Limited (NSE:NATCOPHARM)
Feb 16PDG
Rajeev Nannapaneni (47 yo)
12.2yrs
Titularisation
₹20,920,000
Compensation
Sri Rajeev Nannapaneni serves as Chief Executive Officer at NATCO Pharma Limited since April 1, 2022 and also served as Vice Chairman since June 1, 2012 until April 1, 2022 and serves as its Vice Chairman...
Équipe de direction
| Nom | Position | Titularisation | Compensation | Propriété |
|---|---|---|---|---|
| MD & Chairman | 42.9yrs | ₹22.68m | 25.1% ₹ 69.7b | |
| CEO & Vice Chairman | 12.2yrs | ₹20.92m | 0.63% ₹ 1.7b | |
| Chief Financial Officer | 8.5yrs | ₹13.00m | pas de données | |
| President of Technical Affairs & Whole Time Director | no data | ₹32.30m | 0.030% ₹ 84.0m | |
| Company Secretary & Compliance Officer | 2.3yrs | ₹3.00m | pas de données | |
| Executive VP of Corporate Engineering Services & Whole Time Director | no data | ₹19.20m | 0.023% ₹ 63.8m | |
| Executive VP of Technical Operations & Director | 7.5yrs | ₹54.50m | pas de données | |
| Executive Vice President of Corporate Affairs | no data | pas de données | pas de données | |
| Vice President of Marketing & Sales - Domestic | less than a year | pas de données | pas de données | |
| Senior Vice President of HR & Organisational Development | no data | pas de données | 0.0062% ₹ 17.2m | |
| Executive Vice President of R&D | 30.3yrs | pas de données | 0.025% ₹ 68.4m | |
| Senior Vice President of Demand & Supply Planning | no data | pas de données | pas de données |
7.5yrs
Durée moyenne de l'emploi
65yo
Âge moyen
Gestion expérimentée: L'équipe de direction de NATCOPHARM est chevronnée et expérimentée (ancienneté moyenne 7.5 ans).
Membres du conseil d'administration
| Nom | Position | Titularisation | Compensation | Propriété |
|---|---|---|---|---|
| MD & Chairman | 42.9yrs | ₹22.68m | 25.1% ₹ 69.7b | |
| CEO & Vice Chairman | 18.8yrs | ₹20.92m | 0.63% ₹ 1.7b | |
| President of Technical Affairs & Whole Time Director | 9.5yrs | ₹32.30m | 0.030% ₹ 84.0m | |
| Executive VP of Corporate Engineering Services & Whole Time Director | 9.8yrs | ₹19.20m | 0.023% ₹ 63.8m | |
| Executive VP of Technical Operations & Director | 2yrs | ₹54.50m | pas de données | |
| Independent Director | 10.3yrs | ₹620.00k | pas de données | |
| Independent Director | 9.9yrs | ₹350.00k | pas de données | |
| Independent Director | 9.5yrs | ₹600.00k | pas de données | |
| Independent Director | less than a year | pas de données | pas de données | |
| Independent Director | less than a year | pas de données | pas de données |
9.6yrs
Durée moyenne de l'emploi
69yo
Âge moyen
Conseil d'administration expérimenté: Les membres du conseil d'administration de NATCOPHARM sont considérés comme expérimentés (ancienneté moyenne 9.6 ans).